Cmvpp65-A*0201 Peptide Vaccine

Acute Myeloid Leukemia

City of Hope Medical CentervaccinePhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

588 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
Amsacrine University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-Vincristine Janssen Research & Development, LLC	Phase 3	BBB
Aclacinomycin Chinese PLA General Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Cmvpp65-A*0201 Peptide Vaccine is also rated in:

adult acute lymphoblastic leukemiaDormant

B

Indicative · Phase 2

57 / 100

Hodgkins lymphomaDormant

B

Indicative · Phase 2

57 / 100

chronic myeloid leukemiaDormant

B

Indicative · Phase 2

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.